ClinicalTrials.gg
CompletedNCT05673811VIRAGEUpdated Oct 30, 2026Results posted

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

A Phase 2 interventional study of Nab-paclitaxel and Gemcitabine in Pancreatic Adenocarcinoma and Metastatic, sponsored by Theriva Biologics SL. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Theriva Biologics SL · Phase 2, Interventional, and Treatment

How we know

Updated Oct 30, 2026Results postedStudy documents posted+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 415 studies in Neoplasm Metastasis with a site in Spain — 79 open to participants now, 144 under way, 43 of them phase 3. Neoplasm Metastasis · Spain.

Enrollment
240th of 393
112 · median 163
Started
2023
with 21 others
Phase 2
102 of 415
5 open now
Registered
328th of 415
by date

Among the 415 studies in Neoplasm Metastasis with a site in Spain, this one is the 240th largest by enrollment of the 393 interventional ones that give a count, is one of 22 that started in 2023, is one of 102 in phase 2, and was the 328th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

79 of the 415 studies in Neoplasm Metastasis with a site in Spain are open now. Recruiting first, the newest first:

74 more — sign in →

All 79 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 415 studies in Neoplasm Metastasis with a site in Spain, or all of them as a file.
02

Study summary

A phase IIb, open-label, randomized study of Nab-Paclitaxel and Gemcitabine and plus/minus VCN-01 in Patients with Metastatic Pancreatic Cancer

Read the detailed description

Multi-center, open label, randomized, 2-parallel arm, phase IIb study of nab-paclitaxel and gemcitabine as Standard of Care (SoC) plus/minus VCN-01 in patients with metastatic pancreatic cancer. Gemcitabine and nab-paclitaxel are chemotherapy drugs approved by the FDA to treat pancreatic cancer. VCN-01 is a genetically modified adenovirus characterized by the presence of four independent genetic modifications in the backbone of the wild-type human adenovirus serotype 5 (HAd5) genome that confer tumor selective replication and antitumor activity. Approximately 92 patients in sites in North America and European Union (EU) will be recruited and randomized in a 1:1 ratio to one of two treatment arms (i.e., approximately 46 patients per treatment arm):

  • Arm 1- (SoC): Nab-paclitaxel and gemcitabine as SoC (28-day cycles). Patients in this arm will not receive the investigational medicinal product (IMP) VCN-01.
  • Arm 2- (VCN-01+ SoC): A maximum of two (2) doses of VCN-01 administrated in combination with nab-paclitaxel and gemcitabine as SoC (28-day cycles with exception of the IMP dose cycles, which will be 35-day cycles).

A Data Monitoring Committee (DMC) will be convened at regular intervals to assess safety and to look at OS to determine if the trial can continue.

03

Conditions studied

  • Pancreatic Adenocarcinoma
  • Metastatic

Keywords

  • Cancer
  • Pancreatic adenocarcinoma
  • metastatic
  • oncolytic virus
  • VCN-01
  • Gemcitabine
  • Nab-Paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written obtained prior to any study-specific procedures or assessments.
  2. Male/female patients aged 18 years or over.
  3. Patients with or cytologically confirmed, pancreatic adenocarcinoma stage IV de novo, who never received previous systemic treatment for their pancreatic cancer for which the established therapy is nab-paclitaxel/gemcitabine (clinical SoC). All patients must have at least one measurable tumor lesion that can be imaged for assessments determined by 1.1.
  4. Patients willing to comply with the study treatment.
  5. Patients with a minimum of 5 months.
  6. performance status of 0 or 1.
  7. Use of a reliable method of in fertile men and women. Female patients of (i.e., female patients who are not or surgically sterile) must agree to use effective contraception. Male patients must agree to use effective contraception or be surgically sterile. All male patients must use a male condom.
  8. Adequate baseline organ function (hematologic, liver, renal and nutritional)verified by laboratory analyses performed within 72 hours prior to dosing*:

    Hematology:

    • ≥1.5xE9 /L
    • ≥9 g/dL
    • ≥100xE9/L

    Coagulation (*except in patients on anticoagulants):

    • or international normalized ratio ≤1x (ULN)
    • Activated partial thromboplastin time ≤1.2xULN

    Hepatic:

    • Total ≤1.5xULN
    • and AST ≤2.5xULN (if there are no liver metastases)
    • ALT and AST \<5xULN, and bilirubin \<1.5xULN (if there are liver metastases)

    Renal:

    • Serum creatinine ≤1.5xULN, and if >1.5xULN: Estimated >50 mL/min using Cockcroft and Gault formula

    Nutritional:

    • Serum Albumin ≥30 g/L
    • Note: Adequate organ function specified in this criterion must also be met prior to VCN-01 dosing on Cycle 4 Day 1 for ARM II.

Exclusion criteria

Exclusion Criteria:

<!-- -->

  1. Patients not willing to complete the study procedures for geographic, psychiatric, or social reasons.
  2. Active infection or other serious illness or disease at the moment of randomization. Active infection includes tuberculosis (TB; clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), Virus (HBV; positive HBV surface antigen [HBsAg] result), Virus (HCV; positive HCV Ribonucleic acid [RNA]), or (positive HIV 1/2 antibodies). HBV carriers (patients positive for HBsAg) or those patients requiring antiviral therapy treatment for HBV virus or HCV are not eligible to participate.

    However, the following patients are eligible to participate in the study:

    o Patients with past or resolved TB are eligible;

    o Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [HBcAb] and absence of HBsAg) are eligible. Blood HBV DNA must be obtained and must be negative in these patients prior to treatment;

    o Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.

  3. Treatment with in the last 3 weeks and with the adenovirus type-5 (Ad5)-based COVID-vaccine in the last 12 weeks before the administration of study treatment.
  4. Known chronic liver disease (liver cirrhosis, chronic hepatitis). If there is a suspicion of hepatic fibrosis, a FibroScan must be performed; patients with a value ≥9.5 kPa will be excluded. Note: Transient elastography (Fibroscan) is a non-invasive method for the assessment of hepatic fibrosis.
  5. Treatment with another agent within five of that treatment's half-lives prior to infusion of study treatment.
  6. Viral syndrome diagnosed during the 2 weeks before start of study treatment administration.
  7. Chronic therapy and/or disease modifying therapy, except inhaled , and oral or IV corticosteroids with a dose lower than 10 mg prednisone or equivalent/day (exception: dexamethasone 1 mg/day as maximum).
  8. Concurrent malignant hematologic or solid disease. Patients with a prior history of cancer can be allowed if complete remission for at least 3 years.
  9. Patients in close contact (e.g., living in same house) with immunosuppressed patients (i.e., patients with chronic immunosuppressive therapy including high dose of corticosteroids, patients with acquired immunodeficiency syndrome (AIDS), and other chronic immune system diseases).
  10. Patients with Li Fraumeni syndrome or with previously known retinoblastoma protein pathway germline deficiency.
  11. A female patient, who is pregnant or lactating.
  12. Patients receiving full-dose anticoagulant therapy or in whom these therapies cannot be withdrawn 2 days prior and 2 days after VCN-01 administration. Patients with uncontrolled coagulopathy should be excluded.
  13. Untreated and/or with progressive symptoms despite corticosteroid coverage. Patients with brain metastases with stable symptoms can be included.
  14. Any other condition, disease, metabolic dysfunction (e.g., uncontrolled diabetes mellitus), active or uncontrolled infection/inflammation, physical examination finding, mental state or clinical laboratory finding that would contraindicate participation in the clinical study due to safety concerns or compliance with clinical study procedures.
  15. Patients with previous pneumonitis or interstitial lung disease.
  16. Patients with pre-existing sensory neuropathy >G1.
  17. Patients with known risk factors for bowel perforation.
  18. Patients with corrected by Fridericia (QTcF) assessment >450 ms for men or >470 ms for women and (LVEF) evaluation less than 50% measured by ECHO or multigated acquisition scan.
  19. Known allergy or to any of the study drugs or any of the study drug .
  20. Subjects, for whom treatment options other than the combination Gemcitabine/Nab-Paclitaxel are recommended by the investigator.
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Active comparator
    Arm 1-SoC

    Nab-paclitaxel and gemcitabine as SoC.

    Drug: Nab-paclitaxel · Drug: Gemcitabine

  • Experimental
    Arm 2 -VCN-01 + SoC

    A maximum of two (2) doses of VCN-01 administrated as a single IV infusion in combination with nab-paclitaxel and gemcitabine as SoC.

    Drug: Nab-paclitaxel · Drug: Gemcitabine · Genetic: VCN-01

Interventions

  • DrugAlbumin-Bound PaclitaxelStudies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nab-paclitaxel administered as an IV infusion at a rate of 125 mg/m2. Nab-paclitaxel is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.

  • Gemcitabine administered as an IV infusion at a dose of 1,000 mg/m2 immediately after the completion of nab-paclitaxel administration as part of SoC. Gemcitabine is administered on Day 1, Day 8 and Day 15 of each 28-day cycles.

  • GeneticVCN-01

    VCN-01 administrated as a single IV infusion at dose 1xE13 viral particles (vp) on Day 1 of the 1st cycle and then again on Day 1 of the 4th cycle (Day 92). On cycle 1 and cycle 4, nab-paclitaxel and gemcitabine administered on Day 8, Day 15 and Day 22.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    From date of randomization until the date of death from any cause, assessed up to 27 months

    Time frame: From date of randomization until the date of death from any cause, assessed up to 27 months

  2. Number of TEAEs in Each Treatment Arm

    Safety and tolerability of VCN-01, IV administered at Week 1 and Week 14 in Arm 2 measured as incidence of Adverse Events as assessed by CTCAE v5.0

    Time frame: until the end of treatment period phase

Secondary outcomes

  1. Time to Progression (TTP) or Progression Free Survival (PFS)

    This outcome measure evaluates two related endpoints: Time to Progression (TTP) and Progression-Free Survival (PFS). TTP is defined as the time from randomization to the date of first documented disease progression and assessed up to 27 months. PFS is defined as the time from randomization to the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 27 months.

    Time frame: TTP: From randomization until documented disease progression assessed up to 27 months. PFS: From randomization to either progression or death from any cause assessed up to 27 months.

  2. Overall Response Rate (ORR)

    Objective response rate (ORR) defined as the sum of patients who achieved partial response (PR) plus patients who achieved complete response (CR) using RECIST version 1.1 criteria.

    Time frame: From randomization to partial response or complete response up to 27 months

  3. Disease Control Rate (DCR)

    Disease Control Rate (DCR) defined as: stable disease (SD) + partial response (PR) + complete response (CR)

    Time frame: From randomization to partial response or complete response up to 27 months

  4. Landmark 1-year Survival

    Number of alive participants that were live at the 12-month follow-up period from first enrollment. This measures does not consider the censored patients that had not reached the one-year-Follow-up yet.

    Time frame: From randomization to 1-year landmark

  5. Number of Patients With PFS at the 1-year Landmark

    Number of patients that have progression free survival at the 1-year landmark (n)

    Time frame: From randomization up to 12 months

  6. Duration of Response (DoR)

    Duration of Response (DoR) is defined as the time from the date of first documented objective response (Complete Response \[CR\] or Partial Response \[PR\]) to the date of first documented disease progression, or death from any cause, whichever occurs first. This analysis will only include patients who achieved a confirmed objective response.

    Time frame: From randomization to disease progression assessed up to 27 months

Other outcomes

  1. Neutralizing Anti-VCN-01 Antibodies (Anti-Ad-Nabs)

    Determination of neutralizing anti-VCN-01 antibodies (Anti-Ad-Nabs) in serum of Arm 2 patients at different time-points during the study. Cycle 1 (VCN-01+SoC dosing): Pre-dose, day 8 after first VCN-01 dose, day 8 after second VCN-01 dose.

    Time frame: From randomization up to 27 months

  2. PH20 Levels in Serum

    Determination of PH20 levels in serum of Arm 2 (VCN-01 + SoC) patients at the following time-points: Cycle 1 (VCN-01+SoC dosing): Pre-dose on day 1, 48h post-dose and on day 8; Cycle 2 (SoC dosing): Day 1; Cycle 3 (SoC dosing): Day 1; Cycle 4 (VCN-01+SoC dosing): Pre-dose on day, 48h post-dose and on day 8; On Day 1 of any subsequent SoC cycle.

    Time frame: From pre-dose to end of treatment defined as 1 month after the last dose of nab-paclitaxel/gemcitabine.

  3. VCN-01 Genomes Levels in Blood

    Determination of VCN-01 genomes in whole blood of Arm 2 (VCN-01 + SoC) patients at the following time-points: Cycle 1 (VCN-01+SoC dosing): Pre-dose and 4h post-dose on day 1, 48h post-dose, on day 8 and day 15; Cycle 2 (SoC dosing): Day 1; Cycle 3 (SoC dosing): Day 1; Cycle 4 (VCN-01+SoC dosing): Pre-dose and 4h post dose on day 1, 48h post-dose, on day 8 and day 15; On Day 1 of any subsequent SoC cycle.

    Time frame: From randomization to 27 months

07

Results

Posted Oct 8, 2026

Participant flow

From Dec 20, 2022 through Sep 17, 2024, 171 patients were screened across 17 sites in the US and EU (Spain). 112 participants were randomly allocated to ARM 1-SoC (n=55) or ARM 2-VCN-01+SoC (n=57) in a 1:1 ratio based on the stratification factors ECOG (0 or 1) and geographic region.

Participant flow — Overall Study
MilestoneArm 1-SoCArm 2 -VCN-01 + SoC
Started5557
Completed4853
Not completed74
Withdrew: Withdrawal by subject74

Outcome measures

PrimaryOverall Survival

From date of randomization until the date of death from any cause, assessed up to 27 months

Time frame:
From date of randomization until the date of death from any cause, assessed up to 27 months
Reported as:
Median · months
Overall Survival
monthsArm 1-SoCArm 2 -VCN-01 + SoC
Overall Survival8.6 (6.9 to 11.6)10.8 (7.4 to 15.8)
PrimaryNumber of TEAEs in Each Treatment Arm

Safety and tolerability of VCN-01, IV administered at Week 1 and Week 14 in Arm 2 measured as incidence of Adverse Events as assessed by CTCAE v5.0

Time frame:
until the end of treatment period phase
Reported as:
Number · number of TEAEs in each treatment arm
Number of TEAEs in Each Treatment Arm
number of TEAEs in each treatment armArm 1-SoCArm 2 -VCN-01 + SoC
Number of TEAEs in Each Treatment Arm299399
SecondaryTime to Progression (TTP) or Progression Free Survival (PFS)

This outcome measure evaluates two related endpoints: Time to Progression (TTP) and Progression-Free Survival (PFS). TTP is defined as the time from randomization to the date of first documented disease progression and assessed up to 27 months. PFS is defined as the time from randomization to the date of first documented disease progression or death from any cause, whichever occurs first, assessed up to 27 months.

Time frame:
TTP: From randomization until documented disease progression assessed up to 27 months. PFS: From randomization to either progression or death from any cause assessed up to 27 months.
Reported as:
Median · months
Time to Progression (TTP) or Progression Free Survival (PFS)
monthsArm 1-SoCArm 2 -VCN-01 + SoC
Time to Progression (TTP) or Progression Free Survival (PFS)4.6 (3.5 to 6.5)7.0 (4.8 to 11.2)
SecondaryOverall Response Rate (ORR)

Objective response rate (ORR) defined as the sum of patients who achieved partial response (PR) plus patients who achieved complete response (CR) using RECIST version 1.1 criteria.

Time frame:
From randomization to partial response or complete response up to 27 months
Reported as:
Number · number participants with PR+CR
Overall Response Rate (ORR)
number participants with PR+CRArm 1-SoCArm 2 -VCN-01 + SoC
Overall Response Rate (ORR)1519
SecondaryDisease Control Rate (DCR)

Disease Control Rate (DCR) defined as: stable disease (SD) + partial response (PR) + complete response (CR)

Time frame:
From randomization to partial response or complete response up to 27 months
Reported as:
Number · number of participants with PR+CR+SD
Disease Control Rate (DCR)
number of participants with PR+CR+SDArm 1-SoCArm 2 -VCN-01 + SoC
Disease Control Rate (DCR)3437
SecondaryLandmark 1-year Survival

Number of alive participants that were live at the 12-month follow-up period from first enrollment. This measures does not consider the censored patients that had not reached the one-year-Follow-up yet.

Time frame:
From randomization to 1-year landmark
Reported as:
Number · number of patients alive
Landmark 1-year Survival
number of patients aliveArm 1-SoCArm 2 -VCN-01 + SoC
Landmark 1-year Survival1013
SecondaryNumber of Patients With PFS at the 1-year Landmark

Number of patients that have progression free survival at the 1-year landmark (n)

Time frame:
From randomization up to 12 months
Reported as:
Count of participants · Participants
Number of Patients With PFS at the 1-year Landmark
ParticipantsArm 1-SoCArm 2 -VCN-01 + SoC
Number of Patients With PFS at the 1-year Landmark1013
SecondaryDuration of Response (DoR)

Duration of Response (DoR) is defined as the time from the date of first documented objective response (Complete Response \[CR\] or Partial Response \[PR\]) to the date of first documented disease progression, or death from any cause, whichever occurs first. This analysis will only include patients who achieved a confirmed objective response.

Time frame:
From randomization to disease progression assessed up to 27 months
Reported as:
Median · months
Duration of Response (DoR)
monthsArm 1-SoCArm 2 -VCN-01 + SoC
Duration of Response (DoR)5.4 (1.9 to 6.8)11.2 (7.4 to NA)
Other pre-specifiedNeutralizing Anti-VCN-01 Antibodies (Anti-Ad-Nabs)

Determination of neutralizing anti-VCN-01 antibodies (Anti-Ad-Nabs) in serum of Arm 2 patients at different time-points during the study. Cycle 1 (VCN-01+SoC dosing): Pre-dose, day 8 after first VCN-01 dose, day 8 after second VCN-01 dose.

Time frame:
From randomization up to 27 months
Reported as:
Mean · titer
Neutralizing Anti-VCN-01 Antibodies (Anti-Ad-Nabs)
titerArm 2 -VCN-01 + SoC
Pre-dose273.1 ± 466.4
day 8 after first VCN-01 dose84390 ± 131174
day 8 after second VCN-01 dose18459 ± 18511
Other pre-specifiedPH20 Levels in Serum

Determination of PH20 levels in serum of Arm 2 (VCN-01 + SoC) patients at the following time-points: Cycle 1 (VCN-01+SoC dosing): Pre-dose on day 1, 48h post-dose and on day 8; Cycle 2 (SoC dosing): Day 1; Cycle 3 (SoC dosing): Day 1; Cycle 4 (VCN-01+SoC dosing): Pre-dose on day, 48h post-dose and on day 8; On Day 1 of any subsequent SoC cycle.

Time frame:
From pre-dose to end of treatment defined as 1 month after the last dose of nab-paclitaxel/gemcitabine.

No measurements were reported for this outcome.

Other pre-specifiedVCN-01 Genomes Levels in Blood

Determination of VCN-01 genomes in whole blood of Arm 2 (VCN-01 + SoC) patients at the following time-points: Cycle 1 (VCN-01+SoC dosing): Pre-dose and 4h post-dose on day 1, 48h post-dose, on day 8 and day 15; Cycle 2 (SoC dosing): Day 1; Cycle 3 (SoC dosing): Day 1; Cycle 4 (VCN-01+SoC dosing): Pre-dose and 4h post dose on day 1, 48h post-dose, on day 8 and day 15; On Day 1 of any subsequent SoC cycle.

Time frame:
From randomization to 27 months
Reported as:
Mean · viral particles/ml
VCN-01 Genomes Levels in Blood
viral particles/mlArm 2 -VCN-01 + SoC
Pre-dose1 ± 0
4h after first VCN-01 dose94545434 ± 270506109
4h after second VCN-01 dose128747533 ± 231157542

Adverse events

Collected over All-cause mortality monitored/assessed up to 27 months. Adverse events monitored/assessed from randomization through completion of treatment phase, an average of 1 year. No further adverse events were recorded, unless they were considered related to VCN-01, in accordance with the protocol.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1-SoC35/48 (72.9%)23/48 (47.9%)48/48 (100%)
Arm 2 -VCN-01 + SoC32/53 (60.4%)30/53 (56.6%)52/53 (98.1%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventArm 1-SoCArm 2 -VCN-01 + SoC
Influenza like illnessGeneral disorders0/487/53
Abdominal PainGastrointestinal disorders1/484/53
PyrexiaGeneral disorders2/483/53
CholangitisHepatobiliary disorders2/482/53
Cholangitis acuteHepatobiliary disorders2/482/53
Drug-induced liver injuryHepatobiliary disorders0/482/53
PneumoniaInfections and infestations0/482/53
Toxicity to various agentsInjury, poisoning and procedural complications1/482/53
Transaminases increasedInvestigations0/482/53
Febrile neutropeniaBlood and lymphatic system disorders1/480/53
Most frequent other events
Showing 10 of 33
Most frequent other events
EventArm 1-SoCArm 2 -VCN-01 + SoC
Asthenia /FatigueGeneral disorders36/4848/53
PyrexiaGeneral disorders12/4841/53
NauseaGastrointestinal disorders13/4832/53
Neurotoxicity/Neuropathy peripheralNervous system disorders21/4831/53
Anaemia / Iron deficiencyBlood and lymphatic system disorders23/4828/53
NeutropeniaBlood and lymphatic system disorders18/4827/53
DiarrhoeaGastrointestinal disorders22/4827/53
Transaminases increased /ALT increased/AST increasedInvestigations10/4827/53
Decreased appetiteMetabolism and nutrition disorders20/4827/53
Abdominal PainGastrointestinal disorders13/4826/53

Baseline characteristics

A total of 55 participants were allocated to ARM Standard of Care (SoC) but only 48 participants received the any dose of the study therapy. A total of 57 participants were allocated to ARM VCN-01 + Standard of Care but only 53 participants received any dose of the study therapy.

Age, Continuous
Age, Continuous(years)Control ARM Standard of Care (SoC)Experimental ARM VCN-01 + Standard of Care (SoC)Total
Median68.5 (52 to 85)66.0 (41 to 86)67.6 (41 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)Control ARM Standard of Care (SoC)Experimental ARM VCN-01 + Standard of Care (SoC)Total
Female262753
Male222648
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Control ARM Standard of Care (SoC)Experimental ARM VCN-01 + Standard of Care (SoC)Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American213
White445094
More than one race000
Unknown or Not Reported213
Region of Enrollment
Region of Enrollment(Participants)Control ARM Standard of Care (SoC)Experimental ARM VCN-01 + Standard of Care (SoC)Total
United States7916
Spain414485
ECOG
ECOG(Participants)Control ARM Standard of Care (SoC)Experimental ARM VCN-01 + Standard of Care (SoC)Total
ECOG 0172138
ECOG 1313263
08

Study locations

17 sites
  • Hoag Memorial Hospital Presbyterian
    Newport Beach, California 92663, United States
  • University of California - Davis Cancer Center
    Sacramento, California 95817, United States
  • University of Louisville - Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Weill Cornell Medical Center
    New York, New York 10065, United States
  • Martha Morehouse Tower
    Columbus, Ohio 43221, United States
  • Huntsman Cancer Institute, University of Utah
    Salt Lake City, Utah 84112, United States
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
  • Hospital Universitario Virgen del Rocío
    Seville, Andalusia 41013, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, Barcelona 08035, Spain
  • Hospital Duran i Reynals (ICO)
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
  • Hospital Universitario Marqués de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital Gregorio Marañon
    Madrid, Madrid 28009, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, Madrid 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Madrid 28041, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, Málaga 29010, Spain
  • Hospital General Univesitario de Valencia
    Valencia, Valencia 46014, Spain
  • Hospital Miguel Servet
    Zaragoza, Zaragoza 50009, Spain
09

References and documents

Publications

  • Garcia-Carbonero R, Pazo Cid R, Macarulla T, Laquente B, Nguyen A, Guillen-Ponce C, Munoz A, Kim EJ, Cazorla M, Seery T, Lobo de Mena M, Nevala-Plagemann C, Sharma V, Martinez de Castro E, Hojouj M, Le C, Mato-Berciano A, Connelly S, Kaleko M, Rojas LA, Wacher VJ, Shallcross MA, Blasco C, Cascallo M, Hidalgo M. Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial. Nat Med. 2026 Sep 30. doi: 10.1038/s41591-026-04705-y. Online ahead of print. PubMed 42816596 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Mar 2025, 26 months.

Results were first posted in Oct 2026, 1 year 6 months after primary completion.

Of 88 industry-sponsored phase 2 interventional studies under Neoplasm Metastasis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 63. This study's 26 months is below that.

Counting every sponsor, half of 442 studies reached it within 56 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Jan 6, 2023
StartActual
Jan 10, 2023
Primary completionActual
Mar 28, 2025
CompletionActual
Mar 28, 2025
Results first posted
Oct 8, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Oct 8, 2026 · revised Oct 30, 2026
Sites
9 sites added, 9 sites removed
Show 9 added (9 Spain)
  • Hospital Universitario Virgen del Rocío · Seville, Spain
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • Hospital Duran i Reynals (ICO) · L'Hospitalet de Llobregat, Spain
  • Hospital Gregorio Marañon · Madrid, Spain
  • Hospital Universitario Ramon y Cajal · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Universitario Virgen de la Victoria · Málaga, Spain
  • Hospital General Univesitario de Valencia · Valencia, Spain
  • Hospital Miguel Servet · Zaragoza, Spain
Show 9 removed
  • Hospital Universitario Virgen del Rocío · Sevilla, Spain
  • Hospital Duran i Reynals (ICO) · Hospitalet de Llobregat, Spain
  • Hospital Universitari Vall d'Hebron · Barcelona, Spain
  • Hospital Gregorio Marañon · Madrid, Spain
  • Hospital Universitario Ramon y Cajal · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • Hospital Universitario Virgen de la Victoria · Málaga, Spain
  • Hospital General Univesitario de Valencia · Valencia, Spain
  • Hospital Miguel Servet · Zaragoza, Spain
Oct 8, 2026
Primary outcomes
1 edited, 1 time frame changed, 1 description edited
What changed in the outcomes
  • ChangedBefore Incidence of Adverse Events after VCN-01 IV administrationNow Number of TEAEs in Each Treatment ArmTime frame: From randomization until disease progression assessed up to 3 years → until the end of treatment period phase
  • Time frameOverall SurvivalFrom randomization until death for any cause up to 3 years → From date of randomization until the date of death from any cause, assessed up to 27 months
  • DescriptionOverall Survival: how it is measured was reworded
Oct 8, 2026
Documents
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42816596 ↗
Oct 8, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 8, 2026
  • EditedTime to progressionProgression (TTP) or Progression Free Survival (PFS)Time frame: TTP: From randomization until disease progression assessed up to 3 years or death due to progression.PFS: From randomization to either progression or death from any cause. → TTP: From randomization until documented disease progression assessed up to 27 months. PFS: From randomization to either progression or death from any cause assessed up to 27 months.
  • EditedLandmark 1-year survivalSurvivalTime frame: From randomization to 1-year landmark
  • EditedNumber of Patients With Progression Free Survival (PFS) at the 1-year landmarkLandmarkTime frame: From randomization to1-year landmark → From randomization up to 12 months
  • RemovedChanges in tumor marker Ca 19.9Time frame: From randomization until disease progression assessed up to 3 years
  • Time frameOverall Response Rate (ORR)From randomization until death for any cause up to 3 years → From randomization to partial response or complete response up to 27 months
  • Time frameDisease Control Rate (DCR)From randomization until death for any cause up to 3 years → From randomization to partial response or complete response up to 27 months
  • Time frameDuration of Response (DoR)From randomization to disease progression assessed up to 3 years → From randomization to disease progression assessed up to 27 months
  • DescriptionDuration of Response (DoR): how it is measured was reworded
  • Editedother outcomeNeutralizing antiAnti-VCN-01 antibodiesAntibodies (Anti-Ad-Nabs)Time frame: From pre-dose up to 3 years → From randomization up to 27 months
  • Editedother outcomePH20 levelsLevels in serumSerumTime frame: From pre-dose to end of treatment defined as 1 month after the last dose of nab-paclitaxel/gemcitabine.
  • Editedother outcomeVCN-01 genomes levelsGenomes Levels in bloodBloodTime frame: From pre-dose to end of treatment defined as 1 month after the last dose of nab-paclitaxel/gemcitabine. → From randomization to 27 months
  • Removedother outcomeImmune markersTime frame: From pre-dose to end of treatment defined as 1 month after the last dose of nab-paclitaxel/gemcitabine.
  • Removedother outcomeRadiomicsTime frame: Changes from baseline to every 8 week or every 4 weeks if there is a suspicion of Progressive Disease (PD) not radiologically confirmed during treatment and until disease progression up to 3 years.
  • Removedother outcomeTumor growthTime frame: Changes from baseline to every 8 week or every 4 weeks if there is a suspicion of Progressive Disease (PD) not radiologically confirmed during treatment and until disease progression up to 3 years.
  • Removedother outcomeChanges in Quality of Life (QoL) via the validated Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) version 3.Time frame: From Day 1 in first treatment cycle (35-days) to last follow-up visit up to 3 years.
  • Removedother outcomeDisease Control Rate (DCR) to subsequent therapiesTime frame: From disease progression to exitus for any cause up to 3 years
What changed on Oct 30, 2026
  • EditedNumber of Patients With Progression Free Survival (PFS) at the 1-year LandmarkTime frame: From randomization up to 12 months
across 2 updates, Oct 8, 2026 – Oct 30, 2026
Show all 2 updates
  1. Oct 30, 2026
    Posted results revised
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of Patients With Progression Free Survival (PFS) at the 1-year LandmarkTime frame: From randomization up to 12 months
  2. Oct 8, 2026
    Results posted
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42816596 ↗
    9 sites added, 9 sites removed
    Show 9 added (9 Spain)
    • Hospital Universitario Virgen del Rocío · Seville, Spain
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • Hospital Duran i Reynals (ICO) · L'Hospitalet de Llobregat, Spain
    • Hospital Gregorio Marañon · Madrid, Spain
    • Hospital Universitario Ramon y Cajal · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitario Virgen de la Victoria · Málaga, Spain
    • Hospital General Univesitario de Valencia · Valencia, Spain
    • Hospital Miguel Servet · Zaragoza, Spain
    Show 9 removed
    • Hospital Universitario Virgen del Rocío · Sevilla, Spain
    • Hospital Duran i Reynals (ICO) · Hospitalet de Llobregat, Spain
    • Hospital Universitari Vall d'Hebron · Barcelona, Spain
    • Hospital Gregorio Marañon · Madrid, Spain
    • Hospital Universitario Ramon y Cajal · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • Hospital Universitario Virgen de la Victoria · Málaga, Spain
    • Hospital General Univesitario de Valencia · Valencia, Spain
    • Hospital Miguel Servet · Zaragoza, Spain
    Primary outcomes 1 edited, 1 time frame changed, 1 description edited
    What changed in the outcomes
    • ChangedBefore Incidence of Adverse Events after VCN-01 IV administrationNow Number of TEAEs in Each Treatment ArmTime frame: From randomization until disease progression assessed up to 3 years → until the end of treatment period phase
    • Time frameOverall SurvivalFrom randomization until death for any cause up to 3 years → From date of randomization until the date of death from any cause, assessed up to 27 months
    • DescriptionOverall Survival: how it is measured was reworded
    Secondary outcomes 6 edited, 3 time frame changed, 6 removed, 1 description edited
    What changed in the outcomes
    • EditedTime to progressionProgression (TTP) or Progression Free Survival (PFS)Time frame: TTP: From randomization until disease progression assessed up to 3 years or death due to progression.PFS: From randomization to either progression or death from any cause. → TTP: From randomization until documented disease progression assessed up to 27 months. PFS: From randomization to either progression or death from any cause assessed up to 27 months.
    • EditedLandmark 1-year survivalSurvivalTime frame: From randomization to 1-year landmark
    • EditedNumber of Patients With Progression Free Survival (PFS) at the 1-year landmarkLandmarkTime frame: From randomization to1-year landmark → From randomization up to 12 months
    • RemovedChanges in tumor marker Ca 19.9Time frame: From randomization until disease progression assessed up to 3 years
    • Time frameOverall Response Rate (ORR)From randomization until death for any cause up to 3 years → From randomization to partial response or complete response up to 27 months
    • Time frameDisease Control Rate (DCR)From randomization until death for any cause up to 3 years → From randomization to partial response or complete response up to 27 months
    • Time frameDuration of Response (DoR)From randomization to disease progression assessed up to 3 years → From randomization to disease progression assessed up to 27 months
    • DescriptionDuration of Response (DoR): how it is measured was reworded
    • Editedother outcomeNeutralizing antiAnti-VCN-01 antibodiesAntibodies (Anti-Ad-Nabs)Time frame: From pre-dose up to 3 years → From randomization up to 27 months
    • Editedother outcomePH20 levelsLevels in serumSerumTime frame: From pre-dose to end of treatment defined as 1 month after the last dose of nab-paclitaxel/gemcitabine.
    • Editedother outcomeVCN-01 genomes levelsGenomes Levels in bloodBloodTime frame: From pre-dose to end of treatment defined as 1 month after the last dose of nab-paclitaxel/gemcitabine. → From randomization to 27 months
    • Removedother outcomeImmune markersTime frame: From pre-dose to end of treatment defined as 1 month after the last dose of nab-paclitaxel/gemcitabine.
    • Removedother outcomeRadiomicsTime frame: Changes from baseline to every 8 week or every 4 weeks if there is a suspicion of Progressive Disease (PD) not radiologically confirmed during treatment and until disease progression up to 3 years.
    • Removedother outcomeTumor growthTime frame: Changes from baseline to every 8 week or every 4 weeks if there is a suspicion of Progressive Disease (PD) not radiologically confirmed during treatment and until disease progression up to 3 years.
    • Removedother outcomeChanges in Quality of Life (QoL) via the validated Quality of Life Questionnaire of the European Organization for Research and Treatment of Cancer (EORTC QLQ-C30) version 3.Time frame: From Day 1 in first treatment cycle (35-days) to last follow-up visit up to 3 years.
    • Removedother outcomeDisease Control Rate (DCR) to subsequent therapiesTime frame: From disease progression to exitus for any cause up to 3 years
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05673811
Lead sponsor
Theriva Biologics SL
Responsible party
Sponsor
First posted
Jan 6, 2023
Start date
Jan 10, 2023
Primary completion
Mar 28, 2025
Completion
Mar 28, 2025
Results posted
Oct 8, 2026
Last update
Oct 30, 2026

Study contacts

Tara E Seery, MD
principal investigator · Hoag Memorial Hospital Presbyterian
Edward Kim, MD, PhD
principal investigator · University of California, Davis Cancer Centre
Vivek R Sharma, MD, FACP
principal investigator · University of Louisville, Brown Cancer Center
Alana TH Nguyen, MD, PhD
principal investigator · Weill Medical College of Cornell University
Arjun Mittra, MD
principal investigator · Martha Morehouse Tower
Christopher Nevala-Plagemann, MD
principal investigator · Hunstman Cancer Institute, University of Utah
Alexander Spira, MD, PhD
principal investigator · Virginia Cancer Specialists
Rocío García, MD, PhD
principal investigator · Hospital Universtario 12 de octubre
Teresa Macarulla, Md, PhD
principal investigator · Hospital Vall d'Hebron
Andrés Muñoz, MD, PhD
principal investigator · Hospital Gregorio-Marañon
Carmen Guillén-Ponce, MD, PhD
principal investigator · Hospital Universitario Ramon y Cajal
Miriam Lobo, MD, PhD
principal investigator · Hospital General Universitario de Valencia
Roberto Pazo, MD, PhD
principal investigator · Hospital Miguel Servet
Inmaculada Gallego, MD, PhD
principal investigator · Hospitales Universitarios Virgen del Rocío
Berta Laquente, MD. PhD
principal investigator · Hospital Duran i Reynals (ICO)
Eva Martinez de Castro, MD, PhD
principal investigator · Hospital Universitario Marqués de Valdecilla
Mireya Cazorla, MD, PhD
principal investigator · Hospital Universitario Virgen de la Victoria

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion